Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ceri M Wiggins"'
Autor:
Claire J Cairney, Lauren S Godwin, Alan E Bilsland, Sharon Burns, Katrina H Stevenson, Lynn McGarry, John Revie, Jon D Moore, Ceri M Wiggins, Rebecca S Collinson, Clare Mudd, Elpida Tsonou, Mahito Sadaie, Dorothy C Bennett, Masashi Narita, Christopher J Torrance, W Nicol Keith
Publikováno v:
PLoS Genetics, Vol 13, Iss 8, p e1006942 (2017)
Senescence is a universal barrier to immortalisation and tumorigenesis. As such, interest in the use of senescence-induction in a therapeutic context has been gaining momentum in the past few years; however, senescence and immortalisation remain unde
Externí odkaz:
https://doaj.org/article/9c37fdc4728e4b2584673b3d2d9b5b8b
Autor:
Victor M. Tan, Shengkan Jin, Katarzyna M. Tyc, Melany Ruiz-Urigüen, Jennifer A. Harbottle, Ceri M. Wiggins, Juan Collantes, Jinchuan Xing, John J. Lambourne, Hanlin Tao, Chi Su, Amer Alasadi, Jingjing Guo, Huiting Xu, Tommaso Selmi, Jesse Stombaugh
Publikováno v:
CRISPR J
Conventional CRISPR approaches for precision genome editing rely on the introduction of DNA double-strand breaks (DSB) and activation of homology-directed repair (HDR), which is inherently genotoxic and inefficient in somatic cells. The development o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5b22b5ff1417128252b11da8202ac8a
https://doi.org/10.1089/crispr.2020.0035
https://doi.org/10.1089/crispr.2020.0035
Autor:
Clare Mudd, Ross J. Maxwell, Emma J. Haagensen, Ceri M. Wiggins, Huw D. Thomas, Elpida Tsonou, Jonathan D. Moore, David R. Newell
Publikováno v:
European Journal of Cancer. 56:69-76
Studies to identify predictive biomarkers can be carried out in isogenic cancer cell lines, which enable interrogation of the effect of a specific mutation. We assessed the effects of four drugs, the PI3K-mammalian target of rapamycin inhibitor dacto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc92cfdca53c940ad350c3a7262b0877
https://doi.org/10.1016/j.ejca.2015.12.012
https://doi.org/10.1016/j.ejca.2015.12.012
Autor:
Tim M. Scales, Anett Rada-Kovacs, Helen N. Pemberton, Ceri M. Wiggins, Nicola J. McCarthy, Annette S. Little, David A. Sorrell
Publikováno v:
Cancer Research. 79:1927-1927
Cell panel screening of cancer lines grown in standard 2D conditions is a well-established component of the drug discovery toolbox. A sufficiently large cell line panel, reflecting the molecular heterogeneity within a cancer type/sub-type, is require
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aaaf79ec0fa38e3d9b7cff9668927b82
https://doi.org/10.1158/1538-7445.am2019-1927
https://doi.org/10.1158/1538-7445.am2019-1927
Autor:
Clare Sheridan, David Walter, Carlos le Sage, Paul Russell, Joanne L. Yarker, Nicola McCarthy, Chantelle D. Hudson, Ceri M. Wiggins, Jonathan D. Moore
Publikováno v:
Cancer Research. 78:2912-2912
Genetic perturbations mediated by CRISPR-Cas9 are transforming the drug discovery process. In the hunt for novel drug targets, researchers finally have a screening tool with sufficient penetrance and power to identify new interactions, followed by a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::639e3452f6df470743a549d885239582
https://doi.org/10.1158/1538-7445.am2018-2912
https://doi.org/10.1158/1538-7445.am2018-2912
Publikováno v:
Cellular Signalling. 22:801-808
The pro-apoptotic protein BIM(EL) is phosphorylated by ERK1/2 and this targets the protein for poly-ubiquitination and degradation by the proteasome as a survival mechanism. To define in greater detail the sequence determinants required for BIM(EL) t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef5f9e9acff54113f7f291fb5f5265b8
https://doi.org/10.1016/j.cellsig.2010.01.004
https://doi.org/10.1016/j.cellsig.2010.01.004
Publikováno v:
FEBS Journal. 276:6050-6062
The BCL-2 homology domain 3 (BH3)-only protein, B-cell lymphoma 2 interacting mediator of cell death (BIM) is a potent pro-apoptotic protein belonging to the B-cell lymphoma 2 protein family. In recent years, advances in basic biology have provided a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d4bd0797496e0b000d41b3a0e7bc711
https://doi.org/10.1111/j.1742-4658.2009.07329.x
https://doi.org/10.1111/j.1742-4658.2009.07329.x
Publikováno v:
Cell Cycle. 6:2236-2240
Bim (Bcl-2-interacting mediator of cell death) is a BH3-only protein (BOP), a pro-apoptotic member of the Bcl-2 protein family. The Bim mRNA undergoes alternate splicing to give rise to the short, long and extra long protein variants (Bim(S), Bim(L)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::336ca023177b8a3147e9593a74583b91
https://doi.org/10.4161/cc.6.18.4728
https://doi.org/10.4161/cc.6.18.4728
Autor:
Steffen Lawo, Ceri M. Wiggins
Publikováno v:
Genetic Engineering & Biotechnology News. 36:12-13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::299119ce29f8cfc230b8216088f50ea5
https://doi.org/10.1089/gen.36.04.07
https://doi.org/10.1089/gen.36.04.07
Autor:
Gaganpreet Tiwana, Ceri M. Wiggins, Joanne L. Yarker, David Walter, Chantelle Hudson, Jonathan D. Moore, Paul Russell
Publikováno v:
Molecular Cancer Therapeutics. 16:A25-A25
Mutations in tumour suppressors and un-druggable oncogenes dominate the landscape of cancer driver genes. Only a minority of colon cancers have mutations in druggable cancer drivers, such as PIK3CA. Conversely, mutations in tumour suppressors such as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48db10123cb1e0db7912fac824253c9a
https://doi.org/10.1158/1538-8514.synthleth-a25
https://doi.org/10.1158/1538-8514.synthleth-a25